Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)), Sample Type (Blood) - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
The liquid biopsy market is valued at an estimated USD 6.4 billion in 2024 and is projected to reach USD 11.3 billion by 2029 at a CAGR of 11.9% during the forecast period.
Liquid biopsy presents numerous advantages compared to conventional incisional biopsy techniques, including its non-invasive nature, decreased procedural expenses, easy disease monitoring, and early detection of cancer at its initial stages. These advantages have fueled the acceptance of liquid biopsy procedures by end users. The increasing adoption and acknowledgment of liquid biopsy's benefits over traditional biopsy methods are driving significant advancements in liquid biopsy products and services. 
Assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product & service, during the forecast period.
Based on product & service, the liquid biopsy market is bifurcated into assay kits, instruments, and services. The assay kits segment in the liquid biopsy market is experiencing substantial growth. The recurrent requirement and purchase of these assay kits is one of the primary reasons for the high growth rate of this market segment. The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are other major factors driving the growth of the liquid biopsy assay kits market.
Early cancer screening segment accounted for the highest growth rate in the liquid biopsy market, by clinical application, during the forecast period.
The liquid biopsy market is segmented into into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, based on clinical application. Early cancer screening segment is expected to account for the highest CAGR during the forecast period. The rapid adoption of liquid biopsy technologies for early cancer screeening is fueled by the growing research focus on early cancer detection, coupled with increased funding in this area. This research momentum is translating into a broader range of applications and improved performance of liquid biopsy in early cancer screening, further boosting its growth in this segment.
Asia Pacific: The fastest-growing region in liquid biopsy market.
The worldwide market for liquid biopsy is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is poised to experience the most notable CAGR within the liquid biopsy market. Increasing collaborations between academic institutions, research organizations, and healthcare companies in the Asia Pacific region contribute to the advancement and commercialization of liquid biopsy technologies.
The report provides insights on the following:
- Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the liquid biopsy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, QIAGEN, Myriad Genetics, Illumina and F. Hoffmann-La Roche.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 328 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $6.4 Billion |
| Forecasted Market Value (USD) by 2029 | $11.3 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
Key Topics Covered:
Executive Summary
- Liquid Biopsy Market, by Product & Service, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Circulating Biomarker, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Technology, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Application, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Clinical Application, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Sample Type, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by End-user, 2024 vs. 2029 (USD Million)
- Liquid Biopsy Market, by Region, 2024 vs. 2029 (USD Million)
Premium Insights
- Liquid Biopsy Market Overview - Increasing Demand for Minimally Invasive Diagnostic Techniques to Support Market Growth During Forecast Period
- Liquid Biopsy Market, by Product & Service, 2024 vs. 2029 (USD Million) - Assay Kits Segment to Dominate Market Throughout Forecast Period
- Liquid Biopsy Market, by Circulating Biomarker, 2024 vs. 2029 (USD Million) - Circulating Tumor Cells Segment to Hold Largest Market Share Till 2029
- Liquid Biopsy Market, by Technology, 2024 vs. 2029 (USD Million) - Multi-Gene Parallel Analysis Using NGS Segment to Account for Largest Share of Technology Market
- Liquid Biopsy Market, by Application, 2024 vs. 2029 (USD Million) - Cancer Applications Segment to Retain Market Dominance Till 2029
- Liquid Biopsy Market, by Clinical Application, 2024 vs. 2029 (USD Million) - Therapy Selection and Treatment Monitoring to Hold Largest Market Shares Throughout Forecast Period
- Liquid Biopsy Market, by Sample Type, 2024 vs. 2029 (USD Million) - Blood Samples to Dominate Market Till 2029
- Liquid Biopsy Market, by End-user, 2024 vs. 2029 (USD Million) - Reference Laboratories to Account for Largest Share
- Liquid Biopsy Market: Geographic Growth Opportunities - Asia-Pacific to Register Highest Growth During Forecast Period
Key Market Dynamics
Drivers
- Rising Incidence and Prevalence of Cancer
- Cancer Awareness Initiatives Undertaken by Global Health Organizations
- Benefits of Liquid Biopsy Over Traditional Biopsy Procedures
Restraints
- Lower Sensitivity of Certain Liquid Biopsy Procedures
Opportunities
- Growing Significance of Companion Diagnostics
- Growth Opportunities in Emerging Countries
Challenges
- Unclear Reimbursement Scenario
Key Technologies
- Digital Droplet PCR
- Tagged-Amplicon Deep Sequencing
Complementary Technologies
- Electrochemical Biosensing Technology
Adjacent Technologies
- Microfluidics-based Devices
Case Study Analysis
- Case Study 1: Analytical Validation of Target Selector CTDNA Platform
- Case Study 2: Determining Optimal Mutation Detection Medium
Companies Featured
- Natera
- Qiagen
- Myriad Genetics
- Illumina
- F. Hoffmann-La Roche
- Thermo Fisher Scientific
- Guardant Health
- Bio-Rad Laboratories
- Exact Sciences Corporation
- Sysmex Corporation
- Biocept
- Mdxhealth
- Personalis
- Neogenomics Laboratories
- Epigenomics
- Angle
- Menarini-Silicon Biosystems
- Lunglife AI
- Vortex Biosciences
- Bio-Techne
- Mesa Labs
- Laboratory Corporation of America
- Medgenome
- Strand
- Freenome Holdings
- Lucence Health
For more information about this report visit https://www.researchandmarkets.com/r/3nlt2f
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
